CEP70 and hematologic disorder: Bispecific T-cell engager (BiTE) and chimeric antibody receptor T-cell (CAR-T) therapy have become commonplace for patients with hematologic malignancies, except AML, where lack of suitable surface target unique to AML cells has been a major limitation.